- Home
- TVTX vs CNTA Comparison
TVTX vs CNTA Comparison
Compare TVTX & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TVTX | CNTA |
|---|---|---|
| Founded | N/A | 2020 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.5B |
| IPO Year | 2013 | 2021 |
Fundamental Metrics
Financial Performance| Metric | TVTX | CNTA |
|---|---|---|
| Price | $27.30 | $28.79 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 14 | 9 |
| Target Price | $36.62 | ★ $40.89 |
| AVG Volume (30 Days) | 1.0M | ★ 1.3M |
| Earning Date | 04-30-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 92.89 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $44.62 | N/A |
| Revenue Next Year | $31.76 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $12.91 | $9.60 |
| 52 Week High | $42.13 | $30.58 |
Technical Indicators
Market Signals| Indicator | TVTX | CNTA |
|---|---|---|
| Relative Strength Index (RSI) | 44.77 | 59.34 |
| Support Level | $26.53 | $24.62 |
| Resistance Level | $31.47 | $30.29 |
| Average True Range (ATR) | 1.12 | 1.67 |
| MACD | 0.09 | 0.07 |
| Stochastic Oscillator | 37.03 | 71.92 |
Price Performance
Historical ComparisonAbout TVTX Travere Therapeutics Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.